Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Andromeda Biotech Receives EMEA Support for the Clinical Development Plan of DiaPep277, for the Treatment of Type 1 Diabetes

By Pharmaceutical Processing | November 23, 2009

Andromeda Biotech Ltd. has announced that the European Medicines Agency, (EMEA), has accepted the clinical development plan for DiaPep 277, Andromeda’s lead product for the treatment of type 1 diabetes. The plan submitted by Andromeda includes conducting a confirmatory Phase III study to support the results from the ongoing current Phase III study and will recruit 450 newly diagnosed adult patients (ages 20-45) with type 1 diabetes. About 100 medical centers worldwide, in North America, Europe, South America, and Israel are planned to participate. The goal of the study is to evaluate the long term safety and treatment effect of DiaPep277 to preserve secretion of insulin in diabetic patients. The study will be double blinded with one treatment group and a placebo group. “With the support of the EMEA and following the completion of recruitment in the current ongoing Phase III clinical study, we are very encouraged and will be forging ahead with our clinical development plan in order to pave the way for the drug approval of DiaPep277,” said Dr. Shlomo Dagan, CEO of Andromeda. Andromeda has also submitted the clinical development plan for the Phase III confirmatory study to the FDA for their approval. The Phase III clinical study is scheduled to begin during the first half of 2010.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE